Immunome (IMNM) IPO Opens 31% Higher

Today's IPO for Immunome, Inc. (NASDAQ: IMNM) opened for trading at $15.66 after pricing 3,250,000 shares of common stock at a public offering price of $12.00 per share.

Additionally, Immunome has granted the underwriters a 30-day option to purchase up to an additional 487,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Ladenburg Thalmann & Co. Inc. and Chardan are acting as book-running managers for the offering.

Immunome is a biopharmaceutical company utilizing our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease.

You May Also Be Interested In

• BofA sees growing investor reluctance to fund AI infrastructure
• BeFra Reports Third Quarter 2026 Results
• SK Hynix puts US IPO of chip unit Solidigm on hold after Seoul authorities raise concerns